Japan Pharma Outlook Webinar Recording

Read also

• Datamonitor Healthcare: data analysis and insight, Biomedtra...

  Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

  By Louisa Joseph

  Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

  Topics

  Read Blog

• Datamonitor Healthcare: data analysis and insight

  Webinar: Outlook for NASH Therapies and Market Dynamics

  By Joseph Haas

  Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

  Topics Cell and gene therapy Drug Development Landscape Drug approval

  Full Video

• Awareness, Datamonitor Healthcare: data analysis and insight

  Post-ESMO Podcast 2019

  Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

  Topics Cancer Research

  Full Podcast